These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 37804361)

  • 21. Novel mechanisms and approaches in the medical therapy of solid cancers.
    Awada G; Kourie HR; Awada AH
    Discov Med; 2015; 20(108):33-41. PubMed ID: 26321085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized medicine in oncology: a personal view with myths and facts.
    Beijnen JH; Schellens JH
    Curr Clin Pharmacol; 2010 Aug; 5(3):141-7. PubMed ID: 20406176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-drug conjugates for lung cancer in the era of personalized oncology.
    Ricciuti B; Lamberti G; Andrini E; Genova C; De Giglio A; Bianconi V; Sahebkar A; Chiari R; Pirro M
    Semin Cancer Biol; 2021 Feb; 69():268-278. PubMed ID: 31899248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel points of attack for targeted cancer therapy.
    Røsland GV; Engelsen AS
    Basic Clin Pharmacol Toxicol; 2015 Jan; 116(1):9-18. PubMed ID: 25154903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoconjugates for Cancer Targeting: A Review of Antibody-Drug Conjugates and Antibody-Functionalized Nanoparticles.
    Petrilli R; Pinheiro DP; de Cássia Evangelista de Oliveira F; Galvão GF; Marques LGA; Lopez RFV; Pessoa C; Eloy JO
    Curr Med Chem; 2021; 28(13):2485-2520. PubMed ID: 32484100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current updates on precision therapy for breast cancer associated brain metastasis: Emphasis on combination therapy.
    Raza M; Kumar N; Nair U; Luthra G; Bhattacharyya U; Jayasundar S; Jayasundar R; Sehrawat S
    Mol Cell Biochem; 2021 Sep; 476(9):3271-3284. PubMed ID: 33886058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current methods for the synthesis of homogeneous antibody-drug conjugates.
    Sochaj AM; Świderska KW; Otlewski J
    Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision medicine in clinical oncology: the journey from IgG antibody to IgE.
    Fazekas-Singer J; Singer J; Jensen-Jarolim E
    Curr Opin Allergy Clin Immunol; 2020 Jun; 20(3):282-289. PubMed ID: 32349107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective.
    Dahlgren D; Lennernäs H
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How Can Gastric Cancer Molecular Profiling Guide Future Therapies?
    Corso S; Giordano S
    Trends Mol Med; 2016 Jul; 22(7):534-544. PubMed ID: 27260398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PROTAC: A Novel Drug Delivery Technology for Targeting Proteins in Cancer Cells.
    Bala R; Sindhu RK; Madaan R; Yadav SK
    Curr Drug Discov Technol; 2023; 20(2):e311022210504. PubMed ID: 36321238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
    Gupta A; Ahmad A; Dar AI; Khan R
    Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer.
    Ahuja A; Narde GK; Wadi NMA; Meenakshi DU
    Curr Pharm Des; 2021; 27(45):4593-4609. PubMed ID: 34323183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Overview of Drug Delivery Systems.
    Jain KK
    Methods Mol Biol; 2020; 2059():1-54. PubMed ID: 31435914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
    Zhu H; Wang J; Zhang Q; Pan X; Zhang J
    Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of Target Molecules towards Anti-cancer Therapeutic Antibodies].
    Masuko T
    Yakugaku Zasshi; 2021; 141(1):81-92. PubMed ID: 33390451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoliposomes: A Targeted Drug Delivery System for Cancer Therapeutics and Vaccination.
    Gupta R; Gupta J; Pathak A
    Curr Pharm Biotechnol; 2023; 24(3):366-390. PubMed ID: 35264086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.